source
- J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentWhile innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
- Nurix halts development of BTK degrader zelebrudomide after phase 1 reviewNurix announced it will discontinue clinical development of its BTK degrader zelebrudomide, also known as NX-2127, following completion of enrollment in a phase 1 trial for aggressive non‑Hodgkin l…